Selumetinib for the treatment of non-small cell lung cancer.

about

Role of miR-520b in non-small cell lung cancer

P2860

Q58552553-1BFE9868-DDF4-463A-A188-C3D2D940ED22

P2860

Selumetinib for the treatment of non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q38663069

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Selumetinib for the treatment of non-small cell lung cancer.

@en

type

Item

label

Selumetinib for the treatment of non-small cell lung cancer.

@en

prefLabel

Selumetinib for the treatment of non-small cell lung cancer.

@en

P1476

Selumetinib for the treatment of non-small cell lung cancer.

@en

P2093

Assunta Sgambato

http://www.w3.org/2001/XMLSchema#string

Francesca Casaluce

http://www.w3.org/2001/XMLSchema#string

Giuseppe Santabarbara

http://www.w3.org/2001/XMLSchema#string

Paola Claudia Sacco

http://www.w3.org/2001/XMLSchema#string

Paolo Maione

http://www.w3.org/2001/XMLSchema#string

P2860

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

P304

973-984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1351543

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cesare Gridelli

P577

2017-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28675058

http://www.w3.org/2001/XMLSchema#string

Selumetinib for the treatment of non-small cell lung cancer.

about

P2860

P2860

Selumetinib for the treatment of non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698